Meeting
2011 ASCO Annual Meeting
Clinical outcomes in adult and childhood rhabdomyosarcoma (RMS) treated with vincristine, dactinomycin, and cyclophosphamide (VAC)/VAC-like chemotherapy.
Authors
K. Harano
National Cancer Center Hospital, Tokyo, Japan
K. Harano , Y. Kojima , K. Hashimoto , M. Ando , A. Hirakawa , K. Yonemori , M. Kodaira , M. Yunokawa , C. Shimizu , K. Tamura , N. Katsumata , A. Makimoto , Y. Fujiwara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 29: 2011 (suppl; abstr 10092)
Abstract #
10092
Poster Bd #
51C
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Risk-adapted local therapy and intensive chemotherapy in patients with high-risk rhabdomyosarcoma.
First Author: Michael W. Bishop
Poster
2017 ASCO Annual Meeting
Rhabdomyosarcoma (RMS) in adults: Histologic subtypes and overall survival with actinomycin-based chemotherapy vs doxorubicin-based chemotherapy.
First Author: Alia Vang
Poster
2012 ASCO Annual Meeting
Proton radiotherapy for rhabomyosarcoma: Preliminary results from a multicenter prospective study.
First Author: Torunn I. Yock
Poster
2011 ASCO Annual Meeting
Feasibility of vincristine, dactinomycin, and cyclophosphamide (VAC) chemotherapy for adult rhabdomyosarcoma (RMS) with regard to dose intensity (DI).
First Author: Y. Kojima